IP Library Granted Patent US 7,858,600
Granted Patent B2
US 7,858,600 · App. 10/786,710 · Granted Dec 28, 2010

7- and 9- carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,600
App. No.
10/786,710
Granted
Dec 28, 2010
Kind
B2
Abstract

Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.

Claims (113)

1. A substituted tetracycline compound, wherein said compound is of the formula:

wherein:

X is CR 6′ R 6 ;

R 2 is hydrogen;

R 4 and R 4′ are each alkyl;

R 2′ , R 3 , R 10 , R 11 and R 12 are each hydrogen;

R 5 is hydrogen or hydroxyl;

R 6 and R 6′ are each independently hydrogen or alkyl;

R 7 is hydrogen or NR 7c C(═W′)WR 7a ;

R 8 is hydrogen;

R 9 is hydrogen or NR 9c C(═Z′)ZR 9a ;

Z is O;

Z′ is O or S;

R 9a is substituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted arylcarbonyl, or substituted or unsubstituted phenyl,

wherein said substituted alkyl is substituted with halogen, amino, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl or heteroaryl;

further wherein said substituted alkenyl, substituted alkynyl, substituted alkoxy substituted arylsulfonyl, substituted alkoxycarbonyl, substituted arylcarbonyl, or substituted phenyl is substituted with halogen, amino, alkyl, alkenyl, alkynyl, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl or heteroaryl;

R 9c is hydrogen;

W is CR 7d R 7e , NR 7b or O;

W′ is O or S;

R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, arylsulfonyl, alkoxycarbonyl, arylcarbonyl, alkylamino, phenyl or absent;

or a pharmaceutically acceptable salt thereof, provided that R 9 is not hydrogen when R 7 is hydrogen.

2. The compound of claim 1 , wherein R 4 and R 4′ are each methyl.

3. The compound of claim 2 , wherein R 5 is hydrogen.

4. The compound of claim 3 , wherein X is CH 2 , and R 7 is hydrogen.

5. The compound of claim 2 , wherein R 5 is hydroxyl and X is CHR 6 .

6. The compound of claim 5 , wherein R 6 is CH 3 .

7. The compound of claim 1 , wherein R 9 is NR 9c C(═Z′)ZR 9a .

8. The compound of claim 7 , wherein Z′ is oxygen.

9. The compound of claim 7 , wherein Z′ is sulfur.

10. The compound of claim 7 , wherein R 9a is selected from the group consisting of substituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted phenyl.

11. The compound of claim 10 , wherein said substituted alkyl is substituted with one or more substituents selected from the group consisting of alkoxycarbonyl, amino, arylcarbonyl, halogen, hydroxy, alkylamino, alkoxy, or aryl.

12. The compound of claim 10 , wherein said substituted alkyl is substituted with an aryl group.

13. The compound of claim 12 , wherein said aryl group is phenyl.

14. The compound of claim 10 , wherein said substituted alkyl is substituted with one or more halogens.

15. The compound of claim 14 , wherein said halogen is bromine.

16. The compound of claim 1 , wherein R 9a is substituted or unsubstituted phenyl.

17. The compound of claim 7 , wherein R 9a comprises the group:

18. The compound of claim 16 , wherein said phenyl is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, amido, halogen, nitro, azo, alkyl sulfonyl, and arylsulfonyl.

19. The compound of claim 18 , wherein said substituent is alkyl.

20. The compound of claim 19 , wherein said alkyl is unsubstituted.

21. The compound of claim 19 , wherein said alkyl is methyl.

22. The compound of claim 19 , wherein said alkyl is substituted with one or more halogens.

23. The compound of claim 18 , wherein said substituent is alkoxy and further wherein said alkoxy is methoxy.

24. The compound of claim 18 , wherein said substituent is selected from the group consisting of alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, and amido.

25. The compound of claim 1 , wherein R 7 is NR 7c C(═W′)WR 7a .

26. The compound of claim 25 , wherein R 9 is hydrogen.

27. The compound of claim 26 wherein R 7c is hydrogen.

28. The compound of claim 26 , wherein W′ is O.

29. The compound of claim 26 , wherein W′ is S.

30. The compound of claim 28 or 29 , wherein W is NR 7b .

31. The compound of claim 28 or 29 , wherein W is O.

32. The compound of claim 26 , wherein R 7a is selected from the group consisting of alkyl, alkenyl, alkynyl and phenyl.

33. The compound of claim 32 , wherein R 7a is substituted or unsubstituted alkyl.

34. The compound of claim 33 , wherein said alkyl is substituted with an aryl group.

35. The compound of claim 32 , wherein said phenyl is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, amido, halogen, nitro, azo, alkyl sulfonyl, and arylsulfonyl.

36. The compound of claim 33 , wherein said substituent is alkyl, alkoxy, or nitro.

37. A pharmaceutical composition comprising a therapeutically effective amount of a substituted tetracycline compound and a pharmaceutically acceptable carrier, wherein said substituted tetracycline is of the formula:

wherein:

X is CR 6′ R 6 ;

R 2 is hydrogen;

R 4 and R 4′ are each alkyl;

R 2′ , R 3 , R 10 , R 11 and R 12 are each hydrogen;

R 5 is hydrogen or hydroxyl;

R 6 and R 6′ are each independently hydrogen or alkyl;

R 7 is hydrogen or NR 7c C(═W′)WR 7a ;

R 8 is hydrogen;

R 9 is hydrogen or NR 9c C(═Z′)ZR 9a ;

Z is O;

Z′ is O or S;

R 9a is substituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted arylcarbonyl, or substituted or unsubstituted phenyl;

wherein said substituted alkyl is substituted with halogen, amino, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl or heteroaryl;

further wherein said substituted alkenyl, substituted alkynyl, substituted alkoxy, substituted arylsulfonyl, substituted alkoxycarbonyl, substituted arylcarbonyl, or substituted phenyl is substituted with halogen, amino, alkyl, alkenyl, alkynyl, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl or heteroaryl;

R 9c is hydrogen;

W is CR 7d R 7e , NR 7b or O;

W′ is O or S;

R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, arylsulfonyl, alkoxycarbonyl, arylcarbonyl, alkylamino, phenyl or absent;

or a pharmaceutically acceptable salt thereof, provided that R 9 is not hydrogen when R 7 is hydrogen.

38. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

41. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

42. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

43. The compound of claim 1 , wherein said compound is doxycycline 9-carbamic acid 9H-fluoren-9-yl methyl ester or a pharmaceutically acceptable salt thereof.

44. The compound of claim 1 , wherein said compound is FMOC 9-amino doxycycline or a pharmaceutically acceptable salt thereof.

45. The compound of claim 1 , wherein said compound is 9-(4′-fluorophenyl)doxycycline carbamate or a pharmaceutically acceptable salt thereof.

46. The compound of claim 1 , wherein said compound is 9-(4′-methoxyphenyl)doxycycline carbamate or a pharmaceutically acceptable salt thereof.

47. The compound of claim 1 , wherein said compound is 9-(2′-bromoethyl)doxycycline carbamate or a pharmaceutically acceptable salt thereof.

48. The compound of claim 1 , wherein said compound is 7-(4′-methylphenyl)sancycline carbamate or a pharmaceutically acceptable salt thereof.

49. The compound of claim 1 , wherein said compound is doxycycline 7-carbamic acid 7H-fluoren-7-yl methyl ester or a pharmaceutically acceptable salt thereof.

50. The compound of claim 1 , wherein said compound is 7-(naphthyn-1-yl)doxycycline urea or a pharmaceutically acceptable salt thereof.

51. The compound of claim 1 , wherein said compound is 7-(3-methyl-1-butyl)doxycycline urea or a pharmaceutically acceptable salt thereof.

52. The compound of claim 1 , wherein said compound is 7-phenyl doxycycline urea or a pharmaceutically acceptable salt thereof.

53. The compound of claim 1 , wherein said compound is 7-t-butyl doxycycline urea or a pharmaceutically acceptable salt thereof.

54. The compound of claim 1 , wherein said compound is 7-Fmoc amino doxycycline or a pharmaceutically acceptable salt thereof.

55. The compound of claim 1 , wherein said compound is 7-(4′-chloro-2-trifluoromethylphenyl)doxycycline urea or a pharmaceutically acceptable salt thereof.

56. The compound of claim 1 , wherein said compound is 7-(4′-fluorophenyl)doxycycline carbamate or a pharmaceutically acceptable salt thereof.

57. The compound of claim 1 , wherein said compound is 7-(4′-methoxyphenyl)doxycycline carbamate or a pharmaceutically acceptable salt thereof.

58. The compound of claim 1 , wherein said compound is 7-BOC amino doxycycline or a pharmaceutically acceptable salt thereof.

59. The compound of claim 1 , wherein said compound is 7-(naphthyn-1-yl)doxycycline thiourea 5-propanoic acid ester or a pharmaceutically acceptable salt thereof.

60. The compound of claim 1 , wherein said compound is doxycycline 7-thiocarbamic acid 7H-fluoren-7-yl methyl ester or a pharmaceutically acceptable salt thereof.

61. The compound of claim 1 , wherein said compound is 7-(naphthyn-1-yl)doxycycline thiourea or a pharmaceutically acceptable salt thereof.

62. The compound of claim 1 , wherein said compound is 7-(3-methyl-1-butyl)doxycycline thiourea or a pharmaceutically acceptable salt thereof.

63. The compound of claim 1 , wherein said compound is 7-phenyl amino doxycycline thiourea or a pharmaceutically acceptable salt thereof.

64. The compound of claim 1 , wherein said compound is 7-t-butyl amino doxycycline thiourea or a pharmaceutically acceptable salt thereof.

65. The compound of claim 1 , wherein said compound is 7-(4′-chloro-2′-trifluoromethylphenyl)doxycycline thiourea or a pharmaceutically acceptable salt thereof.

66. The compound of claim 1 , wherein said compound is 7-(4′-fluorophenyl)doxycycline thiocarbamate or a pharmaceutically acceptable salt thereof.

67. The compound of claim 1 , wherein said compound is 7-(4′-methoxyphenyl)doxycycline thiocarbamate or a pharmaceutically acceptable salt thereof.

68. The compound of claim 1 , wherein said compound is 7-(naphthyn-1-yl)doxycycline urea 5-propanoic acid ester or a pharmaceutically acceptable salt thereof.

Assignments (9)
TERMINATION OF LIEN ON PATENTS Recorded Dec 23, 2014
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034700/0377 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →
NOTICE Recorded Mar 8, 2013
From: PARATEK PHARMACEUTICALS, INC.
To: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
Reel/Frame 029940/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2010
From: NELSON, MARK L.; ISMAIL, MOHAMED Y.
To: TRUSTEES OF TUFTS COLLEGE; PARATEK PHARMACEUTICALS, INC.
Reel/Frame 025158/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2010
From: LEVY, STUART B.
To: TRUSTEES OF TUFTS COLLEGE
Reel/Frame 025158/0209 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2010
From: FRECHETTE, ROGER; BOWSER, TODD E.
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 025158/0234 →
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2009
From: MIDCAP FINANCIAL, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 023348/0621 →
SECURITY AGREEMENT Recorded Jul 6, 2009
From: PARATEK PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL, LLC
Reel/Frame 022917/0112 →